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Abstract 
Huntington’s disease is a progressive, degenerative disease 
characterized by abnormal body movements symptoms like chorea and 
a reduction of body weight. Recently, it has been reported that 
oxidative stress, which is one of the pathological hallmarks of various 
neurodegenerative disorders, also plays an important role in the 
pathogenesis of Huntington’s disease.  3- Nitropropionic acid, a 
neurotoxin treatment significantly reduction in body weight.  
Intraperitoneal administration of 3-nitropropionic acid (10 mg/kg  for 
14 days) caused significant loss of body weight and poor rentention of 
memory. Biochemical analysis revealed that 3-NP administration 
significantly increase in lipid peroxidation in the brains of rats.  The 
present study demonstrated that inhibition of type 1 phosphodiesterase 
(PDE1) by vinpocetine    (5, 10 & 20mg\kg) significantly reversed 
behavioral and biochemical dysfunction in 3-NP treated group. The 
result of the present study suggests facilitatory role of PDE1 enzyme in 
loss in body weight and oxidative stress following 3-NP injection.  
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Introduction 
Huntington’s disease is a dominantly inherited 
neurodegenerative disorder characterized by 
progressive worsening chorea, motor impairment 
and psychiatric   disturbances   leading to in 
exorable decay and death1. The degenerative 
process involves medium spiny striatal neurons 
and lesser extent cortical neurons2. To investigate 
the mechanism of neurodegeneration in HD, 
animal models of HD have been generated using 
genetic manipulations, excitotoxins and 
neurotoxins. Injections of NMDA receptor 
agonists, such as qninolinic acid, into the 
striatum, induce HD like pathology, with a loss of 
projecting MSN and sparing of cholinergic and 
NADPH diaphorase neurons3. 3-NP, a 
mycotoxin, is a suicide inhibitor of succinate 
dehydrogenease (SDH), enzyme located in 
mitochondrial inner member. Inhibition of SDH 
interferes with electron cascade and interrupts 
oxidative phosphorylation. This phenomenon 
leads to reduced ATP synthesis and oxidative 
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stress4. Growing body of evidences suggests the 
involvement of impaired energy metabolism, 
excitotoxicity and production of inflammatory 
cytokines leading to neuronal death, by both 
necrosis and apoptosis. These events of 
neurodegeneration are relevant to the striatal cell 
loss seen in HD5.  Elevated levels of oxidative 
damage products, such as malondialdehyde 
(MDA) and 3- nitrotyrosine has been reported in 
areas of degeneration in the HD brain6. The levels 
of cAMP and cGMP are reported to be decreased 
in neuropathological conditions7. cAMP system 
is closely involved in the regulation of important 
BDNF expression too8which play important role 
neuronal survival9, memory & body weight 10. 
Among different iso forms of PDEs, PDE1 is 
found to localize in striatum and cortex, which 
play important role in body weight and motor 
functioning11. Despite substantial research into 
neuroprotection, treatment options for HD are 
still limited to supportive care and the 
management of complications. Currently 
available drugs provide symptomatic relief but do 
not stop progression of disease12. Thus, the 
development of new therapeutic strategies 
remains unmet medical need. Vinpocetine is a 
specific inhibitor of basal and calmodulin- 
activated13 PDE-1. Based on important and 
versatile role of cAMP and cGMP signaling in 
regulation of neuronal functions, the present 
study has been designed to investigate the role of 
PDE1 inhibition in 3-NP induced loss in body 
weight & oxidative stress. Vinpocetine  is well 
known for its antioxidant and anti-cancer  disease 
effects15,16. Recently, neuroprotective effects of 
Vinpocetine have been well reported in an animal 
model of neurodegenerative disease17. Thus the 
present study was carried out to investigate the 
effect of vinpocetine on loss of body weight and 
oxidative stress induced by 3-NP in a rat model 
of HD. 
 
Material and Methods 
Animals  
The experiments were carried out in adult (5-6 
months old) male wistar rats (220-250 g) 
obtained from Central Animal House of I.S.F. 
College of Pharmacy, Moga, Punjab (India). 
They were kept in polyacrylic cages and 
maintained under standard housing conditions 
(room temperature 22±20C and relative humidity 
of 60-65%) with 12h light/dark reverse cycle. 
The food in the form of dry pallets and water 
were made available ad libitum. All behavioural 
experiments were carried out between 10 AM and 
4 PM. The protocol was reviewed and approved 
by the Institutional Animal Ethics Committee and 
the animal experiments were carried out in 
accordance with the Indian National Science 
Academy Guidelines for use and care of animals.  
Drugs and Chemicals  
3-Nitropropionic acid was purchased from 
Sigma-Aldrich Corp. Vinpocetine was provided 
as ex-gratia sample by M/S Covex Pharma Ltd., 
Germany. All other chemicals used in the study 
were of analytical grade. Solutions of the drug 
and chemicals were freshly prepared before use.  
Drugs Administration  
3-NP was diluted with saline (pH 7.4) and 
administrated intraperitoneally at a dose of 10 
mg/kg for 14 days. Vinpocetine was dissolved in 
normal saline containing 1% ascorbic acid and 
administered intraperitoneally at different doses 
viz 5, 10 and 20 mg/kg for 14 days.  
Grouping of Animals  
Animals were divided in five groups and each 
group comprised of five animals.  
 Group 1: Vehicle (normal saline containing 1% 
ascorbic acid, 0.5ml/rat, i.p)  
 Group 2: 3-NP control (10mg/kg, i.p. for 
14days)  
 Group 3: 3-NP+Vinpocetine (5mg/kg, i.p.)  
 Group 4: 3-NP+Vinpocetine (10mg/kg, i.p.)  
 Group 5: 3-NP+Vinpocetine (20mg/kg, i.p.)  
 
3-NP = 3nitropropionic acid and VIN = 
Vinpocetine.  
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Parameters Evaluated 
Measurement of Body Weight 
Body weight was noted on the first   and last days 
of the experiment. Percentage change in the body 
weight was calculated in comparison with the 
initial body weight on the first day of the 
experimentation. 
Body Weight (Ist  day- 15th day)   X100 
Ist day body weight 
Estimation of biochemical parameters 
All the biochemical parameters were measured in 
the brain homogenate on day 15th following 3-NP 
i.p injection. 
Brain homogenate preparation 
Animals were sacrificed and decapitation and 
brains were removed and rinsed with ice -cold 
isotonic saline . Brain tissue samples were then 
homogenized with ice cold  0.1 M phosphate 
buffer (pH  7.4 ) in a volume 10 times the weight 
of the tissue. The homogenate was centrifuged at 
10,000×g for 15 min and aliquots of supernatant 
separated and used for  biochemical estimation. 
Estimation of Malondialdehyde (MDA) 
The quantitative measurement of malonialdehyde 
– the end product of lipid peroxidation –in brain 
homogenate was performed according  to the 
method18. The amount MDA was measured after 
its reaction with thiobarbituric acid at 532 nm 
using spectrophotometer (Shimadzu, UV 1700). 
The concentration of MDA was determined from 
a standard curve expressed as nmol per mg 
protein. 
Result 
Effect of Vinpocetine on  body weight  in 3-NP 
injected rats 
There was no significant difference in the initial 
and final body weight of the vehicle treated 
animals. However, 3-NP treatment caused a 
significant decrease in body weight  on the day 
15th as compared to vehicle treated group. 
Vinpocetine , dose dependently attenuated  the 
decrease in body weight. However, there was no 
significant difference in Vin 10 and 20mg/kg 
dose i.p. (Table 1, Fig 1)  
Evaluation of biochemical parameters 
Malondialdehyde (MDA) Level  
The MDA levels significantly increased on day 
15th  (377.8 ± 16.44 µM/mg protein) following Ist 
3- NP injection as compared to vehicle (144.3 ± 
7.950 µM/mg protein , P< 0.001). Vinpocetine 
shows dose dependent significant decrease in 
MDA levels (5mg/kg , i.p 323.5 ±11.55µ mole 
/mg protein , p< 0.05 ; 10 mg /kg, i.p 218.4 ± 
11.71 µ mole /mg protein, P< 0.001; 20mg /kg , 
i.p 208.2± 12.58 µ mole /mg protein, P< 0.001) 
compared to 3-NP  treated rats (Fig.2, Table 2) 
compared with  those of 3-NP treated animals [ 
Total F (4.49) = 58.29, P<0.001] . Between 
groups viz vehicle and Vin there was no 
significant difference in the levels of MDA [Total 
F(4.49) = 58.29, p> 0.05] (Fig.2, Table 2). 
Statistical analysis  
The results are expressed as means±SD. The 
behavioral values were analyzed by one-way 
analysis of variance (ANOVA) followed by 
Tukey's post hoc test. p < 0.05 was considered 
statistically significant. 
Discussion 
Vinpocetine- (14-ethoxycarbonyl-(3a,16a-ethyl)-
14,15-eburnamine; Cavinton) – a PDE1 inhibitor 
is a synthetic derivative of lesser periwinkle plant 
(Vinca minor) alkaloid. Vincamine is widely used 
as a neuroprotective agent for the prevention and 
treatment of central nervous system disorder of 
cerebrovascular origin 19,20. 3-NP has been 
observed to cause significant reduction in body 
weight and  behavioral abnormalities including 
muscle weakness  and rigidity in animals. 
Huntington’s disease patients often show 
degeneration of hypothalamic neurons and loss of 
body weight21. Reduced body weight can be 
considered as an indicator of 3-NP neurotoxicity.   
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Table.1 Effect of Vinpocetine on % change in body weight in 3-NP treated rats 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values  are expressed as mean ± SD, @ signifies P<0.05 as compared  to vehicle ,*P<   0.05 versus 3-NP 
control, ** P<0.05  versus Vin 5 and 3-NP control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Effect of vinpocetine on body weight in 3-NP treated rats 
 
Values are expressed as mean ± SD, @ signifies P<0.05 as compared to vehicle, *P< 0.05 versus 3-NP 
control, ** P<0.05 versus Vin 5 and 3-NP control rat. 
 
Treatment  % Change in Body weight 
Vehicle  6.100 ± 0.5667 
3-NP  -22.70 ± 1.055 @ 
Vin (5 mg/kg) + 3-NP  -12.30 ± 0.5385* 
Vin (10 mg/kg) + 3-NP  -5 ±0.4216** 
Vin (20 mg/kg) + 3-NP  -4 ±0.3651** 
Vehicle 3 -NP Vin 5 Vin 10 Vin 20
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Table.2 Effect of Vinpocetine on Lipid peroxidation (MDA levels) in brain homogenate of rat 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± SD, @ signifmies P<0.05 as compared to vehicle, *P< 0.05 versus 3-NP 
control, ** P<0.05 versus Vin 5 and 3-NP control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 Effect of Vinpocetine on MDA levels 
Values are expressed as mean ± SD, @ signifies P<0.05 as compared to vehicle, *P< 0.05 versus 3-   NP 
control, ** P<0.05 versus Vin 5 and 3-NP control. 
Treatment  Malondialdehyde  (nm/mg protein)  
Vehicle  144.3± 7.950  
3-NP  377.8± 16.44@  
Vin (5 mg/kg) + 3-NP  323.5 ± 11.55*  
Vin (10 mg/kg) + 3-NP  218.4 ± 11.71**  
Vin (20mg/kg) + 3-NP  208.2 ± 12.58**  
Vehicle 3-NP Vin 5 Vin 10 Vin 20
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Whereas Vinpocetine treatment has been shown 
to significantly improve body weight and 
attenuate 3-NP induced hypoactivity in animals. 
The hypoactivity is a major late stage symptom in 
HD patients22. Loss in body weight and 
hypoactivity could be simply because of 
decreased energy metabolism after 3- NP 
treatment.  3-NP induces energy deficit leads to 
depolarization of membrane potential, followed 
by release of substrate for radical species 
production and consequently oxidative stress 23. 
The lesions occur by a mechanism involving 
secondary excitotoxicity. It has shown that 
excitotoxicity may be linked to free radical 
generation24. Previous evidence for the 
involvement of the oxidative stress in 3-NP 
induced neurotoxicity   includes the production of 
hydroxyl free radicals, changes in endogenous 
antioxidants,and increased in 3- nitrotyrosine , a 
marker of  peroxynitrite – mediated 
damage25.Recently it was reported that systemic 
administration of 3-NP leads to oxidized proteins  
in the striatum and cortex as well as massive loss 
of striatal neurons 26. Moreover, mitochondrial 
dysfunction  and oxidative stress has also been 
implicated in Pathophysiology of HD27. 
Malondialdehyde (MDA) is an  end product of 
lipid peroxidation and it was suggested that 
plasma MDA may be used as potential biomarker 
to test treatment efficacy of drugs used in HD 28. 
Supporting to earlier reports, in the present study 
of 3-NP significantly increased lipid peroxidation 
in rats brain 5,23. Whereas, Vinpocetine treatment 
in these animals has shown to significantly 
attenuate an increase in the levels of MDA 
(indicator of lipid peroxidation due to free 
radicals) following 3-NP administration, 
suggesting antioxidant action of Vinpocetine. In 
addition of Vinpocetine has been demonstrated to 
have antioxidant potential and reported to 
scavenge hydroxyl radicals 29,30. In conclusion, 
using a rodent model system that shows 
impairment in body weight and increase in 
oxidative stress, we obtained results suggesting 
that Vinpocetine has neuroprotective effects 
against 3-NP induced neurotoxicity. In the 
current study, for the first time, we have tried to 
further explore the role of PDE1 inhibition by 
using Vinpocetine as a pharmacological tool in 3-
NP induced neurotoxicity.  
Conclusion  
The present data demonstrate that vinpocetine 
can improve body weight and oxidative -stress in 
3-NP-induced neurotoxicity, an animal model of 
HD. The results suggest that vinpocetine may 
have therapeutic benefit in the treatment of HD.  
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